| Literature DB >> 35999922 |
Ali Khezri1,2, Alireza Mahboub-Ahari1,3, Jafar Sadegh Tabrizi1, Shirin Nosratnejad1,3.
Abstract
Background: Capitation payment is the best-known strategy for paying providers in primary health care. Since health care needs and personal characteristics play an essential role in health care utilization and resource spending, there is a growing tendency on risk adjustment models among health researchers. The objective of this systematic review was to examine the weights used for risk adjustment in primary health care capitation payment.Entities:
Keywords: Capitation; Health Care; Risk Adjustment; Risk Factor; Systematic Review
Year: 2022 PMID: 35999922 PMCID: PMC9386772 DOI: 10.47176/mjiri.36.2
Source DB: PubMed Journal: Med J Islam Repub Iran ISSN: 1016-1430
Fig. 1Summary of the Final Studies
| No | Study | Location | By Region | By Income | Year of the study | Risk Factors for the Capitation Adjustment |
| 1 | Sibley et al, 2012 | Ontario, Canada | NORTH AMERICA | HIGH-INCOME ECONOMIES ($12,236 OR MORE) | 2012 | AGE & SEX - ACG – INCOME |
| 2 | Hindle et al, 2004 | Croatia | EUROPE AND CENTRAL ASIA | UPPER-MIDDLE-INCOME ECONOMIES | 2004 | AGE & SEX |
| 3 | Hindle et al, 2006 | Mongolia | EAST ASIA AND PACIFIC | LOWER-MIDDLE-INCOME ECONOMIES | 2007 | AGE & SEX – INCOME |
| 4 | Shmueli et al, 2014 | Israeli | MIDDLE EAST AND NORTH AFRICA | HIGH-INCOME ECONOMIES ($12,236 OR MORE) | 2014 | AGE – ACG |
| 5 | Wender et al, 2003 | Taiwan | EAST ASIA AND PACIFIC | HIGH-INCOME ECONOMIES ($12,236 OR MORE) | 2003 | AGE & SEX – PIP DCG – TPIP DCG |
| 6 | Chang et al, 2002 | Taiwan | EAST ASIA AND PACIFIC | HIGH-INCOME ECONOMIES ($12,236 OR MORE) | 2002 | AGE & SEX – DCG |
| 7 | Behrend et al. 2007 | Germany | EUROPE AND CENTRAL ASIA | HIGH-INCOME ECONOMIES ($12,236 OR MORE) | 2007 | AGE & SEX - HCC - HOSP - RRW |
| 8 | Vargas et al, 2006 | Chile | LATIN AMERICA AND THE CARIBBEAN | HIGH-INCOME ECONOMIES ($12,236 OR MORE) | 2006 | AGE & SEX – DCG |
| 9 | Yuen et al, 2003 | Umbria, Italy | EUROPE AND CENTRAL ASIA | HIGH-INCOME ECONOMIES ($12,236 OR MORE) | 2003 | AGE & SEX - ACG – PIP DCG |
| 10 | Donato et al, 2006 | Australia | EAST ASIA AND PACIFIC | HIGH-INCOME ECONOMIES ($12,236 OR MORE) | 2006 | AGE & SEX - HCC |
| 11 | Kuhlthau et al, 2005 | The United States | NORTH AMERICA | HIGH-INCOME ECONOMIES ($12,236 OR MORE) | 2005 | AGE & SEX – ACG - DCG – HCC |
| 12 | Pietz et al, 2004 | The United States | NORTH AMERICA | HIGH-INCOME ECONOMIES ($12,236 OR MORE) | 2004 | AGE & SEX – ACG – DCG |
Weight of Risk Factors for Adjusting Capitation
| NO | Study | Demographics & Socioeconomics | Disease Incidence | ||||
| Age & Sex | Income | ACG | DCG | PIP DCG | HCC | ||
| 1 | Sibley and Glazier (2012) - Ontario, Canada | 1.27 | .9302 | 1.17 | - | - | - |
| 2 | Hindle and Kalanj (2004) – Croatia | 1.76 | - | - | - | - | - |
| 3 | Hindle and Khulan (2007) - Mongolia | 1.15 | 1.14 | - | - | - | - |
| 4 | Shmueli (2014) - Israeli | 1.364 | - | 2.375 | - | - | - |
| 5 | Lin.et al. - (2003) – Taiwan | 3.7 | - | - | - | 10.4 | |
| 6 | Chang et al. - (2002) - Taiwan | 3.8 | - | - | 24.7 | - | - |
| 7 | Behrend et al. - (2007) – Germany | 3.1 | - | - | - | - | 11.7 |
| 8 | Vargas and Wasem - (2006) – Chile | .925 | - | .99 | |||
| 9 | Yuen et al. - (2003) - Umbria, Italy | 1.00 | - | 1.00 | - | .65 | - |
| 10 | Donato and Richardson - | 1.001 | - | - | 1.96 | ||
| 11 | Kuhlthau et al. - (2005) – The United States: Georgia New Jersey Wisconsin | 1.017 | - | 1.017 | 1.017 | - | 1.013 |
| 12 | Pietz et al. - (2004) - The United States | 1.05 | - | 1.03 | 1.46 | - | |
| TOTAL | The mean weight or range of the studies | Max: 3.8 | Max: 1.14 | Max: 2.375 | Max: 24.7 | Max: 10.4 | Max: 11.7 |
| Mean (SD) = 1.76 | Mean (SD) = 1.04 | Mean (SD) = 1.32 | Range= (24.7-0.99) | Range= (10.4-0.65) | Range = (11.7-1.01) | ||
PRISMA checklist
| Section/topic | # | Checklist item | Reported on page # | Explanation |
| TITLE | ||||
| Title | 1 |
Identify the report as a systematic review, meta-analysis, or both. | 1 | It is reported in title |
| ABSTRACT | ||||
| Structured summary | 2 |
Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 1 | It is reported in abstract |
| INTRODUCTION | ||||
| Rationale | 3 |
Describe the rationale for the review in the context of what is already known. | 2 | Over the last two decades, various types of risk-adjusting factors have been exploited to improve the predictability of the relevant models. Occasionally, the RA is regarded as a positive technique used to make more development in health systems. Despite the difficulties faced during the RA enhancement, it is still necessary to perform this method. The need for improvement of dominant risk-adjustment systems (RASs) has been confirmed after reviewing the studies the last 15 years |
| Objectives | N/A | - | ||
| Methods | ||||
| Protocol and registration | 5 |
Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 4 |
|
| Eligibility criteria | 6 |
Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. |
Page 6 |
Refer to the result: |
| Methods | ||||
| Information sources | 7 |
Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. |
11-13 |
last searched in March 2017 |
| Search | 8 |
Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. |
SI ( |
supplement information 1 (SI 1) for the PubMed: |
| Study selection | 9 |
State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 4-5 | The survey studies were regarded as eligible for inclusion based on language (English) and content (article of certain methods of RA capitation); the excluded articles were those dealing exclusively with therapies of different diseases/illnesses (not related to RA capitation) and also duplicates. We screened the titles and abstracts of the identified papers and excluded those that were obviously unrelated to our review. |
| Data collection process | 10 |
Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 4-5 | It is reported the data collection process |
| Data items | 11 |
List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 5 | In publishing this manuscript, no funding was received from public finance, commercial or nonprofit organizations. |
| Risk of bias in individual studies | 12 | N/A | - | N/A |
| Summary measures | 13 |
State the principal summary measures (e.g., risk ratio, difference in means). | 5 |
We identified Different factors that influenced capitation payments in the included studies. We categorized the factors in two group "demographic &Socioeconomics factor" (Age & Sex and income) and "disease incidence factor" (Adjusted clinical groups (ACGs), Diagnostic cost groups (DCGs), Principal in patient diagnostic cost groups (PIP-DCGs), Hierarchical coexisting conditions (HCCs)) ( |
| Synthesis of results | 14 | N/A | - | |
| Risk of bias across studies | 15 |
Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | N/A | N/A |
| Additional analyses | 16 |
Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | N/A | N/A |
| Results | ||||
| Study selection | 17 |
Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. |
|
The literature search identified 742 citations, of which 270 were duplicates. We researched 60 full-texts through screening the titles and abstracts. Twelve studies [8, 28-38] met the inclusion criteria ( |
| Study characteristics | 18 |
For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. |
Appendix |
According to the above studies, the influencing factors included demographic and socioeconomic factors (age, gender and income) and disease incidence (adjusted clinical groups, etc.). The characteristics of the included studies are summarized in |
| Risk of bias within studies | 19 |
Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | N/A | |
| Results of individual studies | 20 |
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. |
|
As mentioned above, All the factors indicated in the 12 studies were divided into two subcategories of demographic and socio-economics as well as disease incidence ( |
| Synthesis of results | 21 |
Present results of each meta-analysis done, including confidence intervals and measures of consistency. |
N/A |
N/A |
| Results | ||||
| Risk of bias across studies | 22 |
Present results of any assessment of risk of bias across studies (see Item 15). | N/A | N/A |
| Additional analysis | 23 |
Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | N/A | N/A |
| Discussion | ||||
| Summary of evidence | 24 |
Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 9-10 | According to the applied strategy, the 12 articles from the countries of Canada, Croatia, Mongolia, Israel, Germany, Chile, Italy and Australia (one article each) America and Taiwan (two articles each) were used in the final stage, which were separately evaluated based on various factors involved in capitation adjustment |
| Limitations | 25 |
Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 9-10 | |
| Conclusions | 26 |
Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 9-10 | the best factors which can be effective at any time or place regardless of level of income, geographical location and level of development are the age and gender variables, which have a favorable mean weight compared to other factors. On the other hand, the income factor is the best factor in capitation adjustment in terms of the mean weight of the factor. Generally, the best weight of the factor for capitation adjustment of various countries cannot be certainly determined. However, each country can select its most efficient factor based on the weight of the factor, level of income and geographical condition of the country. |
| Funding | ||||
| Funding | 27 |
Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 10 | In publishing this manuscript, no funding was received from public finance, commercial or non-profit organizations. |
The systematic review search strategies
| PUBMED SEARCH** | |
|
|
|
| SCOPUS SEARCH** | |
| Step 2 | TITLE-ABS(risk adjustment) OR TITLE-ABS(risk factor)AND TITLE-ABS(capitation adjustment ) OR TITLE-ABS("per capita adjustment") OR TITLE-ABS("capitation fee adjustment") OR TITLE-ABS(adjustment capitation ) OR TITLE-ABS("adjustment per capita") OR TITLE-ABS( "adjustment capitation fee") |
| *WEB OF SCIENCE SEARCH* | |
| Step 3 | (TOPIC: (((((capitation adjustment OR "capitation fee adjustment") OR "per capita adjustment") OR adjustment capitation) OR "adjustment per capita") OR "adjustment capitation fee") AND TOPIC: (“risk adjustment” OR “risk factor”)) [185 results] |
| *PROQUEST* | |
| Step 4 | all(capitation adjustment OR "per capita adjustment" OR "capitation fee adjustment" OR adjustment capitation OR "adjustment per capita" OR "adjustment capitation fee") AND all(risk adjustment OR risk factor |
STROBE checklist
|
|
|
| ||||||||||||
| Sibley et al, 2012 | Hindle et al, 2004 | Hindle et al, 2006 | Shmueli et al, 2014 |
Wender et al, | Chang et al, 2002 | Behrend et al. 2007 | Vargas et al, 2006 | Yuen et al, 2003 | Donato et al, 2006 | Kuhlthau et al, 2005 | Pietz et al, 2004 | |||
| Title and abstract | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract | + | + | + | + | + | + | + | + | + | + | + | + |
| (b) Provide in the abstract an informative and balanced summary of what was done and what was found | + | + | + | + | + | + | + | + | + | + | + | + | ||
| Background | 2 | Explain the scientific background and rationale for the investigation being reported | + | + | + | + | + | + | + | + | + | + | + | + |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | + | + | + | + | + | + | + | + | + | + | + | + |
| Study design | 4 | Present key elements of study design early in the paper | + | + | + | + | + | + | + | + | + | + | + | + |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | + | + | + | + | + | + | + | + | + | + | + | + |
| Participants | 6 |
(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | + | + | + | + | + | + | + | + | + | + | + | + |
|
(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed | + | + | + | + | + | + | + | + | + | + | + | + | ||
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | + | + | + | + | + | + | + | + | + | + | + | + |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | + | + | + | + | + | + | + | + | + | + | + | + |
| Bias | 9 | Describe any efforts to address potential sources of bias | + | + | N/A | + | + | + | + | N/A | + | N/A | + | + |
| Study size | 10 | Explain how the study size was arrived at | + | + | + | + | + | + | + | + | + | + | + | + |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | + | + | + | + | + | + | + | + | + | + | + | + |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | + | + | + | + | + | + | + | + | + | + | + | + |
| (b) Describe any methods used to examine subgroups and interactions | + | + | + | + | + | + | + | + | + | + | + | + | ||
| (c) Explain how missing data were addressed | + | + | + | + | + | + | + | + | + | + | + | + | ||
|
(d) Cohort study—If applicable, explain how loss to follow-up was addressed | + | + | + | + | + | + | + | + | + | + | + | + | ||
| (e) Describe any sensitivity analyses | + | + | + | + | + | + | + | + | + | + | + | + | ||
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | + | + | N/A | + | + | + | + | + | + | N/A | N/A | + |
| (b) Give reasons for non-participation at each stage | + | + | N/A | + | + | + | + | + | + | N/A | N/A | + | ||
| (c) Consider use of a flow diagram | + | + | + | + | + | + | + | + | + | + | + | + | ||
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | + | + | + | + | + | + | + | + | + | + | + | + |
| (b) Indicate number of participants with missing data for each variable of interest | + | + | + | + | + | + | + | + | + | + | + | + | ||
| (c) Cohort study—Summarise follow-up time (eg, average and total amount) | + | + | + | + | + | + | + | + | + | + | + | + | ||
| Outcome data | 15* | Cohort study—Report numbers of outcome events or summary measures over time | + | + | + | + | + | + | + | + | + | + | + | + |
| Case-control study—Report numbers in each exposure category, or summary measures of exposure | + | + | + | + | + | + | + | + | + | + | + | + | ||
| Cross-sectional study—Report numbers of outcome events or summary measures | + | + | + | + | + | + | + | + | + | + | + | + | ||
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | + | + | + | + | + | + | + | + | + | + | + | + |
| (b) Report category boundaries when continuous variables were categorized | + | + | + | + | + | + | + | + | + | + | + | + | ||
| (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | + | + | + | + | + | + | + | + | + | + | + | + | ||
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | + | + | + | + | + | + | + | + | + | + | + | + |
| Key results | 18 | Summarise key results with reference to study objectives | + | + | + | + | + | + | + | + | + | + | + | + |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | + | + | + | + | + | + | + | + | + | + | + | + |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | + | N/A | N/A | N/A | + | + | + | + | + | + | + | + |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | N/A | + | N/A | + | + | N/A | + | N/A | + | N/A | N/A | N/A |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | + | N/A | N/A | + | N/A | N/A | N/A | + | + | N/A | + | N/A |